Skip to main content

Table 1 Characteristics of all patients between MSD and AD

From: Alternative donor peripheral blood stem cell transplantation for the treatment of high-risk refractory and/or relapsed childhood acute leukemia: a randomized trial

Variables MSD(n = 42) AD(n = 69) χ2 P value
Gender (n, %) 0.172 0.678
 Male 27 (64.3) 47 (68.1)
 Female 15 (35.7) 22 (31.9)
Primary disease (n, %) 0.016 0.899
 AML 22 (52.4) 37 (53.6)
 ALL 20 (47.6) 32 (46.4)
Disease status at HSCT (n, %) 1.873 0.392
 First CR 19 (45.2) 39 (56.5)
 Second and other CR 16 (38.1) 18 (26.1)
 Relapse 7 (16.7) 12 (17.4)
Disease status at HSCT (n, %) 1.332 0.248
 First CR 19 (45.2) 39 (56.5)
 Other 23 (54.8) 30 (43.5)
Extramedullary infiltration (n, %) 2.538 0.111
 Yes 8 (19.0) 6 (8.7)
 No 34 (81.0) 63 (91.3)
Conditioning regimen (n, %) 0.082 0.775
 Bu/Cy-based 30 (71.4) 51 (73.9)
 TBI/Cy-based 12 (28.6) 18 (26.1)
Gender of donor-recipient (n, %) 5.669 0.017
 Identical 19 (45.2) 47 (68.1)
 Different 23 (54.8) 22 (31.9)
Donor-recipient ABO compatibility (n, %) 0.014 0.907
 Compatible 19 (45.2) 32 (46.4)
 Incompatible 23 (54.8) 37 (53.6)
Abnormal markers NA NA
 t(9;22) 8 (19.0) 13 (18.8)
 MLL/AF4 1 (2.4) 3 (4.3)
 FLT3/ITD 2 (4.8) 1 (1.4)
MRD 0.014 0.906
 Yes 12 (28.6) 19 (27.5)
 No 30 (71.4) 50 (72.5)
MNC (× 108/kg) 11.74 (3.98–31.03) 14.57 (3.57–47.11) NA NA
CD34 + cells(× 106/kg) 5.84 (3.43–23.30) 8.33 (3.07–35.7) NA NA
Time for implantation of neutrophils (d) 12 (9–19) 13 (10–26) NA NA
Time for implantation of PLT(d) 13 (8–30) 13 (9–26) NA NA
  1. MSD matched sibling donor, AD alternative donor, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, HSCT hematopoietic stem cell transplantation, CR complete remission, BU busulfan, TBI total body irradiation, Cy cyclophosphamide, MRD minimal residual disease MNC mononuclear cells, PLT platelet, NA not applicable